Immunomodulatory Properties of Human Adult and Fetal Multipotent Mesenchymal Stem Cells

Overview

Journal J Biomed Sci

Publisher Biomed Central

Specialty Biology

Date 2011 Jul 19

PMID 21762539

Citations 72

Authors

Pei-Min Chen

Men-Luh Yen

Ko-Jiunn Liu

Huey-Kang Sytwu

B-Linju Yen

Affiliations

Soon will be listed here.

Abstract

In recent years, a large number of studies have contributed to our understanding of the immunomodulatory mechanisms used by multipotent mesenchymal stem cells (MSCs). Initially isolated from the bone marrow (BM), MSCs have been found in many tissues but the strong immunomodulatory properties are best studied in BM MSCs. The immunomodulatory effects of BM MSCs are wide, extending to T lymphocytes and dendritic cells, and are therapeutically useful for treatment of immune-related diseases including graft-versus-host disease as well as possibly autoimmune diseases. However, BM MSCs are very rare cells and require an invasive procedure for procurement. Recently, MSCs have also been found in fetal-stage embryo-proper and extra-embryonic tissues, and these human fetal MSCs (F-MSCs) have a higher proliferative profile, and are capable of multilineage differentiation as well as exert strong immunomodulatory effects. As such, these F-MSCs can be viewed as alternative sources of MSCs. We review here the current understanding of the mechanisms behind the immunomodulatory properties of BM MSCs and F-MSCs. An increase in our understanding of MSC suppressor mechanisms will offer insights for prevalent clinical use of these versatile adult stem cells in the near future.

Citing Articles

Human fetal lung mesenchymal stem cells ameliorate lung injury in an animal model.

Golmohammadi M, Sheikhha M, Ganji F, Shirani A, Barati M, Kalantar S Sci Rep. 2025; 15(1):6433.

PMID: 39984612 PMC: 11845704. DOI: 10.1038/s41598-025-91406-0.

The role of fetal pancreatic islet cell transplantation in the treatment of type 2 diabetes mellitus.

Kaibagarova I, Saparbaev S, Aringazina R, Zhumabaev M, Nurgaliyeva Z J Diabetes Metab Disord. 2024; 23(2):1949-1957.

PMID: 39610528 PMC: 11599508. DOI: 10.1007/s40200-024-01448-w.

Revolutionizing medicine: recent developments and future prospects in stem-cell therapy.

Hussen B, Hussen B, Taheri M, Yashooa R, Abdullah G, Abdullah S Int J Surg. 2024; 110(12):8002-8024.

PMID: 39497543 PMC: 11634165. DOI: 10.1097/JS9.0000000000002109.

Anticancer peptides as novel immunomodulatory therapeutic candidates for cancer treatment.

Sood A, Jothiswaran V, Singh A, Sharma A Explor Target Antitumor Ther. 2024; 5(5):1074-1099.

PMID: 39351437 PMC: 11438574. DOI: 10.37349/etat.2024.00264.

Bone marrow-derived mesenchymal stem cells reduce CCl-induced kidney injury and fibrosis in male Wistar rats.

Adel A, Abdul-Hamid M, Abdel-Kawi S, A Abdelaziz M, Sakr H, Ahmed O Ren Fail. 2024; 46(2):2319330.

PMID: 39049729 PMC: 11275530. DOI: 10.1080/0886022X.2024.2319330.

References

Kern S, Eichler H, Stoeve J, Kluter H, Bieback K . Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006; 24(5):1294-301. DOI: 10.1634/stemcells.2005-0342. View

Rouas-Freiss N, Goncalves R, Menier C, Dausset J, Carosella E . Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis. Proc Natl Acad Sci U S A. 1997; 94(21):11520-5. PMC: 23525. DOI: 10.1073/pnas.94.21.11520. View

Sioud M, Mobergslien A, Boudabous A, Floisand Y . Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. Int J Oncol. 2010; 38(2):385-90. DOI: 10.3892/ijo.2010.869. View

In t Anker P, Noort W, Kruisselbrink A, Scherjon S, Beekhuizen W, Willemze R . Nonexpanded primary lung and bone marrow-derived mesenchymal cells promote the engraftment of umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol. 2003; 31(10):881-9. DOI: 10.1016/s0301-472x(03)00202-9. View

Spaggiari G, Abdelrazik H, Becchetti F, Moretta L . MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood. 2009; 113(26):6576-83. DOI: 10.1182/blood-2009-02-203943. View

Chan W, Lau A, Li J, Law H, Lau Y, Chan G . MHC expression kinetics and immunogenicity of mesenchymal stromal cells after short-term IFN-gamma challenge. Exp Hematol. 2008; 36(11):1545-55. DOI: 10.1016/j.exphem.2008.06.008. View

Groh M, Maitra B, Szekely E, Koc O . Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol. 2005; 33(8):928-34. DOI: 10.1016/j.exphem.2005.05.002. View

Erices A, Conget P, Minguell J . Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol. 2000; 109(1):235-42. DOI: 10.1046/j.1365-2141.2000.01986.x. View

FRIEDENSTEIN A, PETRAKOVA K, Kurolesova A, Frolova G . Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation. 1968; 6(2):230-47. View

10.

Kronsteiner B, Peterbauer-Scherb A, Grillari-Voglauer R, Redl H, Gabriel C, van Griensven M . Human mesenchymal stem cells and renal tubular epithelial cells differentially influence monocyte-derived dendritic cell differentiation and maturation. Cell Immunol. 2010; 267(1):30-8. DOI: 10.1016/j.cellimm.2010.11.001. View

11.

Zhou H, Yi D, Yu S, Sun G, Cui Q, Zhu H . Administration of donor-derived mesenchymal stem cells can prolong the survival of rat cardiac allograft. Transplant Proc. 2006; 38(9):3046-51. DOI: 10.1016/j.transproceed.2006.10.002. View

12.

English K, Ryan J, Tobin L, Murphy M, Barry F, Mahon B . Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol. 2009; 156(1):149-60. PMC: 2673753. DOI: 10.1111/j.1365-2249.2009.03874.x. View

13.

Francois M, Romieu-Mourez R, Stock-Martineau S, Boivin M, Bramson J, Galipeau J . Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood. 2009; 114(13):2632-8. DOI: 10.1182/blood-2009-02-207795. View

14.

Liotta F, Angeli R, Cosmi L, Fili L, Manuelli C, Frosali F . Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells. 2007; 26(1):279-89. DOI: 10.1634/stemcells.2007-0454. View

15.

Batten P, Sarathchandra P, Antoniw J, Tay S, Lowdell M, Taylor P . Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Tissue Eng. 2006; 12(8):2263-73. DOI: 10.1089/ten.2006.12.2263. View

16.

Chang C, Yen M, Chen Y, Chien C, Huang H, Bai C . Placenta-derived multipotent cells exhibit immunosuppressive properties that are enhanced in the presence of interferon-gamma. Stem Cells. 2006; 24(11):2466-77. DOI: 10.1634/stemcells.2006-0071. View

17.

Zhang Y, Li C, Jiang X, Zhang S, Wu Y, Liu B . Human placenta-derived mesenchymal progenitor cells support culture expansion of long-term culture-initiating cells from cord blood CD34+ cells. Exp Hematol. 2004; 32(7):657-64. DOI: 10.1016/j.exphem.2004.04.001. View

18.

Li Y, Paczesny S, Lauret E, Poirault S, Bordigoni P, Mekhloufi F . Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol. 2008; 180(3):1598-608. DOI: 10.4049/jimmunol.180.3.1598. View

19.

Giordano A, Galderisi U, Marino I . From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol. 2007; 211(1):27-35. DOI: 10.1002/jcp.20959. View

20.

Le Blanc K, Samuelsson H, Gustafsson B, Remberger M, Sundberg B, Arvidson J . Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia. 2007; 21(8):1733-8. DOI: 10.1038/sj.leu.2404777. View